The pharmacokinetics and pharmacodynamics of losartan in continuous ambulatory peritoneal dialysis

Journal of Clinical Pharmacology

Volumn 40, Issue 4, 2000, Pages 389-395

  Pedro, Antonio A ^a   Gehr, Todd W B ^a   Brophy, Donald F ^b   Sica, Domenic A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 BUTYL 4 CHLORO 1 [[2' (1H TETRAZOL 5 YL) 4 BIPHENYLYL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ALDOSTERONE; ENDOTHELIN; LOSARTAN; NORADRENALIN; RENIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG TOLERABILITY; FEMALE; HEMODIALYSIS; HORMONAL REGULATION; HUMAN; HYPERTENSION; KIDNEY FAILURE; MALE;

ADULT; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; BLOOD PRESSURE; DIASTOLE; FEMALE; HALF-LIFE; HUMANS; IMIDAZOLES; KIDNEY FAILURE, CHRONIC; LOSARTAN; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; SYSTOLE; TETRAZOLES;

EID: 0033635423     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700022009099     Document Type: Article

References (27)

1. Blood pressure effects of the angiotensin II receptor blocker, losartan
2. Losartan: First of a new class of angiotensin antagonists for the management of hypertension
3. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans
4. Clinical pharmacology of multiple-dose losartan, an angiotensin II receptor antagonist, in patients with essential hypertension
5. The pharmacokinetics of losartan in renal insufficiency
6. The pharmacokinetics and pharmacodynamics of losartan in maintenance hemodialysis
7. Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes: Role of cytochrome P4503A (4) in formation of the active metabolite EXP3174
8. Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes: Role of cytochrome P4502C and 3A subfamily members
9. Human plasma protein binding of the angiotensin II receptor antagonist losartan potassium (DUP 753/MK 964) and its pharmacologically active metabolite EXP3174
10. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans
11. Evaluation of the losartan in hemodialysis study
12. Peritoneal equilibration test
13. A simple HPLC method for determination of losartan and E-3174 in human plasma, urine, and dialysate utilizing mid-bore chromatography
14. Pharmacokinetics of intravenous and oral losartan in patients with heart failure
15. Impairment of drug biotransformation in renal disease: An in vitro model
16. Characterization of mRNA species related to liver cytochrome P-450 nifedipine oxidase and the regulation of catalytic activity
17. The clinical pharmacology of losartan in Japanese subjects and patients
18. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist
19. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers
20. Effect of acute and chronic losartan therapy on active and inactive renin and active renin glycoforms
21. Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients
22. Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension
23. Changes of plasma endothelin and growth factor levels, and of left ventricular mass, after chronic AT1-receptor blockade in human hypertension
24. Interactions of the renin-angiotensin system and the sympathetic system
25. The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis
26. Peritoneal clearances in hypertensive CAPD patients after oral administration of clonidine, enalapril, and nifedipine
27. Hormonal, blood pressure, and peritoneal transport response to short-term ACE inhibition